Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study
- 11 February 2022
- journal article
- research article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 56, 100-111
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric PatientsJAMA Network Open, 2020
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsClinical Pharmacology & Therapeutics, 2015
- Clinical applications of CYP genotyping in psychiatryJournal of Neural Transmission, 2014
- Emergency Department Visits by Adults for Psychiatric Medication Adverse EventsJAMA Psychiatry, 2014
- Data Structures for Statistical Computing in PythonProceedings of the Python in Science Conference, 2010
- Toward achieving optimal response: understanding and managing antidepressant side effectsDialogues in clinical neuroscience, 2008
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006
- Role of pharmacologically active metabolites in drug discovery and developmentDrug Discovery Today, 2006
- SSRI Antidepressant MedicationsThe Primary Care Companion For CNS Disorders, 2001
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987